Aspire Biopharma Partners with Microsize for Alprazolam Development
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 03 2026
0mins
Should l Buy ASBP?
Aspire Biopharma announced a strategic partnership with Microsize. Aspire has engaged Microsize to accelerate the development of a novel sublingual powder formulation of alprazolam, the active pharmaceutical ingredientI in the widely prescribed anti-anxiety medication Xanax.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ASBP?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ASBP
About ASBP
Aspire Biopharma Holdings, Inc. is an early-stage biopharmaceutical company. It develops and markets a technology for novel delivery mechanisms for FDA approved drugs, nutraceuticals, and supplements. It has developed and acquired technologies that are a Novel Soluble Formulation which address emergencies and drug efficacy, dosage management, and response time. Its Sublingual Aspirin Product, which addresses cardiology emergencies and pain management, is a granular or powder formulation of a soluble, Ph-neutral, fast-acting aspirin. It also has numerous pharmaceutical and nutraceutical applications under development in various areas, including but not limited to a Viagra/Cialis combination product which is faster acting, requiring decreased dosages with the benefit of a longer half-life, various bi-hormonal drugs such as testosterone, estrogen and weight loss drugs, and thyroid drugs, as well as various supplements including a rapid-absorbing pre-workout and a melatonin sleep aid.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Box Inc Q4 Earnings Exceed Expectations
- Earnings Beat: Box Inc reported Q4 earnings of $0.49 per share, surpassing the consensus estimate of $0.34, indicating a significant improvement in profitability that boosts investor confidence.
- Revenue Growth: The company achieved quarterly revenue of $305.88 million, exceeding the Street estimate of $304.28 million and reflecting a 9.4% increase from $279.52 million in the same period last year, showcasing sustained business momentum.
- Stock Surge: Box Inc's shares jumped 6.2% to $25.40 in pre-market trading, demonstrating a positive market reaction to the earnings report, which may attract more investor interest.
- Optimistic Market Outlook: The earnings beat not only enhances Box Inc's market image but also potentially provides funding for future investments and expansions, further solidifying its competitive position in the cloud storage market.
See More
Aspire Biopharma Raises $21M Through Preferred Shares Sale
- Funding Size: Aspire Biopharma has entered into a securities purchase agreement to raise up to $21 million by selling 26,250 Series A Convertible Preferred Shares at $800 each, indicating strong market confidence in its financing capabilities.
- Initial Closing: The company completed an initial closing on February 6, 2026, issuing 13,750 shares for $11 million in gross proceeds, which will support legacy operations and strategic initiatives.
- Compliance Support: This financing is expected to help Aspire regain compliance with Nasdaq's stockholders' equity requirements, enhancing its stability and attractiveness in the capital markets.
- Market Reaction: Aspire Biopharma's shares rose 12% in premarket trading, reflecting investor optimism about the company's future prospects, which may further boost its market performance.
See More
Aspire Biopharma Regains Nasdaq Compliance
- Compliance Notice: Aspire Biopharma has received formal notification from Nasdaq confirming that it has regained compliance with the $1 minimum bid price requirement, which is expected to enhance investor confidence and stabilize its stock price.
- Equity Requirement: Despite regaining compliance, Aspire remains subject to an extension period to demonstrate compliance with Nasdaq's $2.5 million stockholders' equity requirement, which is crucial for the company's financing capabilities and market reputation.
- Stock Price Reaction: ASBP shares rose 2% in premarket trading, reflecting a positive market response to the company's compliance restoration, potentially attracting more investor interest.
- Financial Transparency: Recent financial disclosures from Aspire Biopharma highlight its efforts towards compliance, bolstering market confidence in its future growth, particularly in the context of seeking further financing and business expansion.
See More
Aspire Biopharma Submits Pre-IND Request to FDA for Fast-Acting Sublingual Aspirin with Significant Clinical Benefits
- FDA Submission Progress: Aspire submitted its Pre-IND meeting request to the FDA on November 3, 2025, for its fast-acting sublingual aspirin, marking a significant milestone that is expected to accelerate the clinical development process toward potential FDA approval.
- Breakthrough Clinical Data: Clinical trials demonstrated that Aspire's sublingual aspirin inhibits platelet aggregation in under two minutes, acting approximately four to five times faster than chewed aspirin, which holds significant clinical implications for improving treatment outcomes in heart attack patients.
- Substantial Market Potential: With over 800,000 people in the U.S. experiencing heart attacks annually, Aspire's product could provide a faster and more reliable treatment option, addressing the urgent market demand for effective medical solutions.
- Optimized Regulatory Pathway: Aspire plans to pursue a 505(b)(2) regulatory pathway, which allows the FDA to consider data from previously approved drugs, potentially reducing development time and costs, thereby enhancing its competitive position in the market.
See More
Gorilla Technology Shares Rise Approximately 14%; Check Out 20 Stocks Making Moves in Premarket Trading
Gorilla Technology Group Performance: Gorilla Technology Group Inc. reported a 32% year-over-year revenue increase to $26.5 million for Q3, leading to a 13.7% rise in its share price during pre-market trading.
Other Gainers in Pre-Market Trading: Notable stocks that surged include Olema Pharmaceuticals (up 53%), Lobo Technologies (up 40.3%), and Aspire Biopharma (up 30.7%), among others.
Losers in Pre-Market Trading: LifeMD Inc. saw a significant drop of 26.2% after disappointing financial results, while Alpha Technology Group and NextPlat Corp also experienced notable declines.
Market Overview: The pre-market trading session showed a mix of gains and losses across various stocks, with some companies reporting strong earnings while others faced setbacks.
See More
Friday's Major Stock Market Highlights: Morning News Summary!
- Trading Week Overview: The article discusses the closing of the trading week and highlights key stock market stories from Friday.
- Top Headlines: A list of the most significant headlines related to the stock market is provided for readers to explore.
See More
Box Inc Q4 Earnings Exceed Expectations
- Earnings Beat: Box Inc reported Q4 earnings of $0.49 per share, surpassing the consensus estimate of $0.34, indicating a significant improvement in profitability that boosts investor confidence.
- Revenue Growth: The company achieved quarterly revenue of $305.88 million, exceeding the Street estimate of $304.28 million and reflecting a 9.4% increase from $279.52 million in the same period last year, showcasing sustained business momentum.
- Stock Surge: Box Inc's shares jumped 6.2% to $25.40 in pre-market trading, demonstrating a positive market reaction to the earnings report, which may attract more investor interest.
- Optimistic Market Outlook: The earnings beat not only enhances Box Inc's market image but also potentially provides funding for future investments and expansions, further solidifying its competitive position in the cloud storage market.
See More
Aspire Biopharma Raises $21M Through Preferred Shares Sale
- Funding Size: Aspire Biopharma has entered into a securities purchase agreement to raise up to $21 million by selling 26,250 Series A Convertible Preferred Shares at $800 each, indicating strong market confidence in its financing capabilities.
- Initial Closing: The company completed an initial closing on February 6, 2026, issuing 13,750 shares for $11 million in gross proceeds, which will support legacy operations and strategic initiatives.
- Compliance Support: This financing is expected to help Aspire regain compliance with Nasdaq's stockholders' equity requirements, enhancing its stability and attractiveness in the capital markets.
- Market Reaction: Aspire Biopharma's shares rose 12% in premarket trading, reflecting investor optimism about the company's future prospects, which may further boost its market performance.
See More
Aspire Biopharma Regains Nasdaq Compliance
- Compliance Notice: Aspire Biopharma has received formal notification from Nasdaq confirming that it has regained compliance with the $1 minimum bid price requirement, which is expected to enhance investor confidence and stabilize its stock price.
- Equity Requirement: Despite regaining compliance, Aspire remains subject to an extension period to demonstrate compliance with Nasdaq's $2.5 million stockholders' equity requirement, which is crucial for the company's financing capabilities and market reputation.
- Stock Price Reaction: ASBP shares rose 2% in premarket trading, reflecting a positive market response to the company's compliance restoration, potentially attracting more investor interest.
- Financial Transparency: Recent financial disclosures from Aspire Biopharma highlight its efforts towards compliance, bolstering market confidence in its future growth, particularly in the context of seeking further financing and business expansion.
See More
Aspire Biopharma Submits Pre-IND Request to FDA for Fast-Acting Sublingual Aspirin with Significant Clinical Benefits
- FDA Submission Progress: Aspire submitted its Pre-IND meeting request to the FDA on November 3, 2025, for its fast-acting sublingual aspirin, marking a significant milestone that is expected to accelerate the clinical development process toward potential FDA approval.
- Breakthrough Clinical Data: Clinical trials demonstrated that Aspire's sublingual aspirin inhibits platelet aggregation in under two minutes, acting approximately four to five times faster than chewed aspirin, which holds significant clinical implications for improving treatment outcomes in heart attack patients.
- Substantial Market Potential: With over 800,000 people in the U.S. experiencing heart attacks annually, Aspire's product could provide a faster and more reliable treatment option, addressing the urgent market demand for effective medical solutions.
- Optimized Regulatory Pathway: Aspire plans to pursue a 505(b)(2) regulatory pathway, which allows the FDA to consider data from previously approved drugs, potentially reducing development time and costs, thereby enhancing its competitive position in the market.
See More
Gorilla Technology Shares Rise Approximately 14%; Check Out 20 Stocks Making Moves in Premarket Trading
Gorilla Technology Group Performance: Gorilla Technology Group Inc. reported a 32% year-over-year revenue increase to $26.5 million for Q3, leading to a 13.7% rise in its share price during pre-market trading.
Other Gainers in Pre-Market Trading: Notable stocks that surged include Olema Pharmaceuticals (up 53%), Lobo Technologies (up 40.3%), and Aspire Biopharma (up 30.7%), among others.
Losers in Pre-Market Trading: LifeMD Inc. saw a significant drop of 26.2% after disappointing financial results, while Alpha Technology Group and NextPlat Corp also experienced notable declines.
Market Overview: The pre-market trading session showed a mix of gains and losses across various stocks, with some companies reporting strong earnings while others faced setbacks.
See More
Friday's Major Stock Market Highlights: Morning News Summary!
- Trading Week Overview: The article discusses the closing of the trading week and highlights key stock market stories from Friday.
- Top Headlines: A list of the most significant headlines related to the stock market is provided for readers to explore.
See More
